This study is testing a new treatment called EG110A for adults who have bladder control problems (neurogenic detrusor overactivity, or NDO) due to a spinal cord injury. You might be able to join if you are between 18 and 75 years old, have had a stable spinal cord injury for at least 12 months, and experience incontinence (unintended urine leakage) even after standard treatments. You also need to regularly use a catheter to empty your bladder. Researchers want to see how safe EG110A is and what doses might work best. They will also look at how well EG110A helps with bladder control, using information from a bladder diary and special bladder tests. The study is currently unclear on its recruitment status and plans to enroll 16 participants.

Study design

This is an open-label, dose-escalation study, meaning everyone knows what treatment is being given, and the dose of EG110A will be gradually increased. It is a first-in-human study, which means it's one of the first times this treatment is being given to people.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will follow up for one year to track any side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.